Lilly’s Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer’s disease

The authorization in Australia is for adult patients who are Apolipoprotein E-ε4 heterozygotes or non-carriers INDIANAPOLIS, May 21, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted marketing…